bioRxivMicrobiology
Peptidoglycan associated cyclic lipopeptide disrupts viral infectivity
B. A. Johnson, A. Hage, B. Kalveram, M. Mears, J. A. Plante, S. E. Rodriguez, Z. Ding, X. Luo, D. Bente, S. S. Bradrick, A. N. Freiberg, V. Popov, R. Rajsbaum, S. Rossi, W. K. Russell, V. D. Menachery
Abstract
Enteric viruses exploit bacterial components including lipopolysaccharides (LPS) and peptidoglycan (PG) to facilitate infection in humans. With origins in the bat enteric system, we wondered if severe acute respiratory syndrome-coronavirus (SARS-CoV) or Middle East respiratory syndrome-CoV (MERS-CoV) also use bacterial components to modulate infectivity. To test this question, we incubated CoVs with LPS and PG and evaluated infectivity finding no change following LPS treatment. However, PG from B. subtilis reduced infection >10,000-fold while PG from other bacterial species failed to recapitulate this. Treatment with an alcohol solvent transferred inhibitory activity to the wash and mass spectrometry revealed surfactin, a cyclic lipopeptide antibiotic, as the inhibitory compound. This antibiotic had robust dose- and temperature-dependent inhibition of CoV infectivity. Mechanistic studies indicated that surfactin disrupts CoV virion integrity and surfactin treatment of the virus inoculum ablated infection in vivo. Finally, similar cyclic lipopeptides had no effect on CoV infectivity and the inhibitory effect of surfactin extended broadly to enveloped viruses including influenza, Ebola, Zika, Nipah, Chikungunya, Una, Mayaro, Dugbe, and Crimean-Congo hemorrhagic fever viruses. Overall, our results indicate that peptidoglycan-associated surfactin has broad virucidal activity and suggest bacteria byproducts may negatively modulate virus infection.\n\nImportanceIn this manuscript, we considered a role for bacteria in shaping coronavirus infection. Taking cues from studies of enteric viruses, we initially investigated how bacterial surface components might improve CoV infection. Instead, we found that peptidoglycan-associated surfactin is a potent viricidal compound that disrupts virion integrity with broad activity against enveloped viruses. Our results indicate that interactions with commensal bacterial may improve or disrupt viral infections highlighting the importance of understanding these microbial interactions and their implications for viral pathogenesis and treatment.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cellulosic copper nanoparticles and a hydrogen peroxide-based disinfectant protect Vero E6 cells against infection by viral pseudotyped particles expressing SARS-CoV-2, SARS-CoV or MERS-CoV Spike protein.
- Specific bacterial cell wall components influence the stability of Coxsackievirus B3
A. H. Dhalech, T. D. Fuller, C. M. Robinson·bioRxiv·May 14, 2021
- Inhibition of SARS-CoV-2 infection by Porphyromonas gingivalis and the oral microbiome
Alexander Bontempo, Alexandra Chirino, … Mark J. Cayabyab·Microbiology SpectrumPeer-reviewed·Aug 20, 2024
- Virion stripping: A new role for bacterial proteases
Carlos J. Rodriguez Hernandez, Marina Terekhova, … Juhi Bagaitkar·bioRxiv·May 3, 2025
- Microbiota-Independent Antiviral Effects of Antibiotics on Enteric Viruses
M. A. Woods Acevedo, J. K. Pfeiffer·bioRxiv·Feb 14, 2020
- Broad-spectrum virucidal activity of bacterial secreted lipases against flaviviruses, SARS-CoV-2 and other enveloped viruses